In conclusion, this study shows that MEG3 enhances cisplatin sensitivity in cervical cancer cells by regulating the miR-21/PTEN axis, and that MEG3 acts as a ceRNA of the miR-21/PTEN axis to exert oncogenic effects and influence cisplatin resistance in cervical cancer. The gene discussed is PTEN; the disease is cervical cancer.